Home > others & > Fosaprepitant dimeglumine salt

Fosaprepitant dimeglumine salt

福沙吡坦二甲葡胺,MK-0517,MK 0517,MK0517

Fosaprepitant dimeglumine 是神经激肽-1受体拮抗剂，可作用于化疗引起的恶心呕吐。

目录号
EY0975
EY0975
EY0975
EY0975

纯度
99.65%
99.65%
99.65%
99.65%

规格
5 mg
10 mg
50 mg
100 mg

原价
520
715
2400
4200

售价
520
715
2400
4200

库存
现货
现货
现货
现货

订购
订购
订购
订购
订购
订购

具体折扣请咨询客服

生物活性

Fosaprepitant is a water-soluble phosphoryl prodrug for Aprepitant which is a NK1 antagonist.
体外研究
体内研究
激酶实验
细胞实验
动物实验
不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数

例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

参考文献

[1] Navari RM. Expert Opin Investig Drugs, 2007, 16(12), 1977-1985.

分子式 C37H56F7N6O16P	分子量 1004.83	CAS号 265121-04-8	储存方式 ﹣20 ℃冷藏长期储存。冰袋运输
溶剂（常温）	DMSO 200 mg/mL	Water 140 mg/mL	Ethanol <1 mg/mL

体内溶解度

Clinical Trial Information ( data from http://clinicaltrials.gov )

NCT Number	Conditions	Interventions	Sponsor/Collaborators	Phases	Start Date	Last Updated
NCT01220388	Male\|Healthy Volunteers	Dietary Supplement: L-lysine\|Dietary Supplement: placebo	University Hospital, Rouen		2010-10-01	2013-06-17
NCT01275664	Malignant Ovarian Mixed Epithelial Tumor\|Nausea and Vomiting\|Ovarian Brenner Tumor\|Ovarian Clear Cell Cystadenocarcinoma\|Ovarian Endometrioid Adenocarcinoma\|Ovarian Mucinous Cystadenocarcinoma\|Ovarian Serous Cystadenocarcinoma\|Stage II Ovarian Cancer\|Stage IIA Fallopian Tube Cancer\|Stage IIA Ovarian Cancer\|Stage IIB Fallopian Tube Cancer\|Stage IIB Ovarian Cancer\|Stage IIC Fallopian Tube Cancer\|Stage IIC Ovarian Cancer\|Stage IIIA Fallopian Tube Cancer\|Stage IIIA Ovarian Cancer\|Stage IIIA Primary Peritoneal Cancer\|Stage IIIB Fallopian Tube Cancer\|Stage IIIB Ovarian Cancer\|Stage IIIB Primary Peritoneal Cancer\|Stage IIIC Fallopian Tube Cancer\|Stage IIIC Ovarian Cancer\|Stage IIIC Primary Peritoneal Cancer\|Stage IV Fallopian Tube Cancer\|Stage IV Ovarian Cancer\|Stage IV Primary Peritoneal Cancer\|Undifferentiated Ovarian Carcinoma	Procedure: Adjuvant Therapy\|Drug: Aprepitant\|Drug: Carboplatin\|Drug: Cisplatin\|Drug: Dexamethasone\|Drug: Granisetron Transdermal Patch\|Procedure: Management of Therapy Complications\|Other: Questionnaire Administration	Gynecologic Oncology Group\|National Cancer Institute (NCI)		2011-06-01	2016-03-16

注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

相关化合物库
使用AMQUAR产品发表文献后请联系我们

相关推荐

X